Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PGEN with free AI briefings, catalyst countdowns, and dilution alerts.

PGEN · PRECIGEN, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$51M Cash on Hand
51.6mo Cash Runway
Follow PGEN by email Get an email when PGEN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PGEN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Zopapogene Imadenovec (PRGN-2012) Recurrent Respiratory Papillomatosis Phase 4 · NCT06538480 Recruiting
Zopapogene imadenovec-drba Recurrent Respiratory Papillomatosis (RRP) Phase 3 · NCT07901738 Not yet recruiting
AG019 - High Dose Diabetes type1 Phase 1/2 · NCT03751007 Completed
Gorilla-derived Adenovirus-expressing HPV-16/18… Cervical Cancer Phase 2 · NCT06157151 Recruiting
Fludarabine Chronic Lymphocytic Leukemia Phase 1 · NCT05694364 Completed
INXN-4001 Heart Failure Phase 1 · NCT03409627 Completed
Autologous Anti-MUC16 CAR-mbIL15-Safety Switch… Platinum-Resistant Fallopian Tube Carcinoma Phase 1 · NCT03907527 Active not recruiting
Autologous Anti-CD33 CAR-mbIL15-Safety Switch… Acute Myeloid Leukemia Phase 1 · NCT03927261 Active not recruiting
Autologous Anti-ROR1 CAR-mbIL15-Safety… Chronic Lymphocytic Leukemia Phase 1 · NCT05694364 Completed

Also used in these trials (approved or third-party drugs, not PGEN's own candidates): Teplizumab, Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PGEN holds $51M in cash and short-term investments (as of Sep 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 51.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PGEN files for a raise →

👥 Who Owns PGEN

Insiders 39.7% Institutions (305 holders) 60.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Randal J Kirk
Director, 10% owner
Insider 133,956,416 37.36% 2026-03-30
Patient Capital Management, LLC Institution (13G, 5%+) 36,006,800 10.04% 2025-12-31
Helen Sabzevari
President and CEO · +2.10M options
Insider 3,779,521 1.05% 2026-08-23
Steven Frank
Director
Insider 1,226,391 0.34% 2026-03-13
Cesar L Alvarez
Director
Insider 782,909 0.22% 2026-03-13
Donald P. Lehr
Chief Legal Officer · +415,292 options
Insider 758,181 0.21% 2026-08-23
Vinita D Gupta
Director
Insider 666,027 0.19% 2026-03-13
Rutul R Shah
Chief Operating Officer · +525,596 options
Insider 468,865 0.13% 2026-08-21
Harry Jr. Thomasian
Chief Financial Officer · +1.37M options
Insider 311,914 0.09% 2026-09-23
Nancy H Agee
Director
Insider 309,187 0.09% 2026-08-21
Phil Tennant
Chief Commercial Officer · +563,126 options
Insider 141,992 0.04% 2026-08-23
Jeffrey B Kindler
Director
Insider 17,100 0.00% 2026-08-26

Share count 358,549,980 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-08-27 PAPZIMEOS BLA +169.6% +7.8% +11.5%

Browse all historical PDUFA outcomes →

Get the full PGEN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PGEN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.